Seminars in Hematology
Volume 40, Issue 3 , Pages 213-220 , July 2003

Survival signals in leukemic large granular lymphocytes

  • P.K. Epling-Burnette

      Affiliations

    • *Address correspondence to P.K. Epling-Burnette, PhD, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    • Hematology Malignancy Program, H. Lee Moffitt Cancer Center and Research Institute, University of South FloridaTampa, FL, USA
    • James A. Haley Veterans’ Administration Hospital, Tampa, FL, USA
    • ,
  • Thomas P. Loughran Jr

      Affiliations

    • Hematology Malignancy Program, H. Lee Moffitt Cancer Center and Research Institute, University of South FloridaTampa, FL, USA
    • James A. Haley Veterans’ Administration Hospital, Tampa, FL, USA

References 

  1. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science. 1998;281:1322–1326
  2. Alderson MR, Tough TW, Davis-Smith T, et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;18:71–77
  3. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev. 1998;8:55–62
  4. Algeciras-Schimnich A, Shen L, Barnhart BC, et al.  Molecular ordering of the initial signaling events of CD95. Mol Cell Biol. 2002;22:207–220
  5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  6. Aprile JA, Russo M, Pepe MS, et al.  Activation signals leading to proliferation of normal and leukemic CD3+ large granular lymphocytes. Blood. 1991;78:1282–1285
  7. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science. 1998;281:1305–1308
  8. Bettinardi A, Brugnoni D, Quiros-Roldan E, et al.  Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood. 1997;89:902–909
  9. Boldin MP, Goncharov TM, Goltsev YV, et al.  Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 1996;85:803–815
  10. Bredesen DE. Apoptosis: Overview and signal transduction pathways. J Neurotrauma. 2000;17:801–810
  11. Buettner R, Mora LB, Jove R, et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945–954
  12. Cascino I, Fiucci G, Papoff G, et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706–2713
  13. Cascino I, Papoff G, De Maria R, et al.  Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol. 1996;156:13–17
  14. Catlett-Falcone R, Landowski TH, Oshiro MM, et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115
  15. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1:41–49
  16. Chang HY, Yang X. Proteases for cell suicide: Functions and regulation of caspases. Microbiol Mol Biol Rev. 2000;64:821–846
  17. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40
  18. Cheng J, Zhou T, Lin C, et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–1762
  19. Chinnaiyan AM, O’Rourke K, Tewari M, et al.  FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505–512
  20. Cohen JJ, Duke RC, Fadok VA, et al.  Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992;10:267–293
  21. de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 1998;10:619–628
  22. de Saint Basile G, Fischer A. The role of cytotoxicity in lymphocyte homeostasis. Curr Opin Immunol. 2001;13:549–554
  23. DerSimonian H, Sugita M, Glass DN, et al.  Clonal V alpha 12.1+ T cell expansions in the peripheral blood of rheumatoid arthritis patients. J Exp Med. 1993;177:1623–1631
  24. Deveraux QL, Roy N, Stennicke HR, et al.  IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215–2223
  25. Dhein J, Walczak H, Baumer C, et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373:438–441
  26. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351–362
  27. Fisher GH, Rosenberg FJ, Straus SE, et al.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–946
  28. Garcia R, Yu CL, Hudnall A, et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997;8:1267–1276
  29. Gentile TC, Uner AH, Hutchinson RE, et al.  CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood. 1994;84:2315–2321
  30. Goltsev YV, Kovalenko AV, Arnold A, et al.  CASH, a novel caspase homologue with death effector domains. J Biol Chem. 1997;272:19641–19644
  31. Holmstrom TH, Schmitz I, Soderstrom TS, et al.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J. 2000;19:5418–5428
  32. Holmstrom TH, Tran SE, Johnson VL, et al.  Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 1999;19:5991–6002
  33. Hu S, Vincenz C, Buller M, et al.  A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem. 1997;272:9621–9624
  34. Hu S, Vincenz C, Ni J, et al.  I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem. 1997;272:17255–17257
  35. Irmler M, Thome M, Hahne M, et al.  Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–195
  36. Itoh N, Yonehara S, Ishii A, et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–243
  37. Ju ST, Panka DJ, Cui H, et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444–448
  38. Kasten-Sportes C, Zaknoen S, Steis RG, et al.  T-cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: Preferential V alpha but diverse J alpha usage in one of five patients. Blood. 1994;83:767–775
  39. Kischkel FC, Hellbardt S, Behrmann I, et al.  Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579–5588
  40. Knipping E, Krammer PH, Onel KB, et al.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 1995;38:1735–1737
  41. Kothapalli R, Bailey RD, Kusmartseva I, et al.  Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003;22:33–39
  42. Lamy T, Drenou B. Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol. 1998;100:509–515
  43. Lamy T, Liu JH, Landowski TH, et al.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998;92:4771–4777
  44. Lamy T, Loughran TP. Current concepts: Large granular lymphocyte leukemia. Blood Rev. 1999;13:230–240
  45. Lanier LL. Face off—The interplay between activating and inhibitory immune receptors. Curr Opin Immunol. 2001;13:326–331
  46. Lanier LL. On guard—Activating NK cell receptors. Nat Immunol. 2001;2:23–27
  47. Li H, Zhu H, Xu CJ, et al.  Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491–501
  48. Liston P, Roy N, Tamai K, et al.  Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379:349–353
  49. Liu JH, Wei S, Lamy T, et al.  Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002;100:1449–1453
  50. Loughran TP. Clonal diseases of large granular lymphocytes. Blood. 1993;82:1–14
  51. Loughran TP, Draves KE, Starkebaum G, et al.  Induction of NK activity in large granular lymphocyte leukemia: Activation with anti-CD3 monoclonal antibody and interleukin 2. Blood. 1987;69:72–78
  52. Loughran TP, Hadlock KG, Perzova R, et al.  Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol. 1998;101:318–324
  53. Loughran TP, Hadlock KG, Yang Q, et al.  Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3− (natural killer) lymphoproliferative disease of granular lymphocytes. Blood. 1997;90:1977–1981
  54. Loughran TP, Kadin ME, Starkebaum G, et al.  Leukemia of large granular lymphocytes: Association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102:169–175
  55. Loughran TP, Sherman MP, Ruscett F, et al.  Prototypical HTLV-I/II infection is rare in LGL leukemia. Leuk Res. 1994;18:423–429
  56. Loughran TP, Starkebaum G, Aprile JA, et al.  Rearrangement and expression of T-cell receptor genes in large granular lymphocyte leukemia. Blood. 1988;71:822–824
  57. Marshall CJ. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179–185
  58. Marte BM, Downward J. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997;22:355–358
  59. Medema JP, Scaffidi C, Kischkel FC, et al.  FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997;16:2794–2804
  60. Meier P, Finch A, Evan G, et al.  Apoptosis in development. Nature. 2000;407:796–801
  61. Miyawaki T, Uehara T, Nibu R, et al.  Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol. 1992;149:3753–3758
  62. Moretta A, Bottino C, Vitale M, et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197–223
  63. Muzio M, Chinnaiyan AM, Kischkel FC, et al.  FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1997;85:817–827
  64. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  65. Oksenberg JR, Panzara MA, Begovich AB, et al.  Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 1993;362:68–70
  66. Ortaldo JR, Mason AT, Nagata S, et al.  Receptor-induced death in human natural killer cells: Involvement of CD16. J Exp Med. 1995;181:339–344
  67. Ortaldo JR, Winkler-Pickett RT, O’Sea JJ. Fas involvement in human NK cell apoptosis: Lack of a requirement for CD16-mediated events. J Leukoc Biol. 1995;61:209–215
  68. Oshimi K, Shinkai Y, Okumura K, et al.  Perforin gene expression in granular lymphocyte proliferative disorders. Blood. 1990;75:704–708
  69. Owen-Schaub LB, Yonehara S, Crump WL, et al.  DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 1992;140:197–205
  70. Papoff G, Cascino I, Erama A, et al.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol. 1996;156:4622–4630
  71. Phillips JH, Lanier LL. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen. J Immunol. 1986;136:1579–1585
  72. Podack ER, Hengartner H, Lichtenheld MG. A central role of perforin in cytolysis?. Annu Rev Immunol. 1991;9:129–157
  73. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol. 1999;17:781–828
  74. Refaeli Y, Van Parijs L, London CA, et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8:615–623
  75. Ritz J, Campen TJ, Schmidt RF, et al.  Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science. 1985;228:1540–1543
  76. Roy N, Deveraux QL, Takahashi R, et al.  The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16:6914–6925
  77. Russell JH, Rush B, Weaver C, et al.  Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA. 1993;90:4409–4413
  78. Scaffidi C, Fulda S, Srinivasan A, et al.  Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675–1687
  79. Semenzato G, Pandolfi F, Chisesi T, et al.  The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60:2971–2978
  80. Shresta S, MacIvor DM, Heusel JW, et al.  Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA. 1995;92:5679–5683
  81. Shu HB, Halpin DR, Goeddel DV, et al.  Casper is a FADD- and caspase-related inducer of apoptosis. Immunity. 1997;6:751–763
  82. Simonian PL, Grillot DA, Nunez G, et al.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 1997;90:1208–1216
  83. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1994;1:365–371
  84. Soderstrom TS, Poukkula M, Holstrom TH, et al.  Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J Immunol. 2002;169:2851–2860
  85. Sottini A, Bettinardi A, Quiros-Roldan E, et al.  Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome. Blood. 1995;86:2240–2247
  86. Spits H, Yssel H, Leeuwenberg J, et al.  Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol. 1985;15:88–91
  87. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, et al.  Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA. 1996;93:14486–14491
  88. Srinivasula SM, Ahmad M, Dttilie S, et al.  FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem. 1997;272:18542–18545
  89. Takahashi A, Day NK, Luangwedchakarn V, et al.  A retroviral-derived immunosuppressive peptide activates mitogen-activated protein kinases. J Immunol. 2001;166:6771–6775
  90. Takahashi T, Tanaka M, Brannan CI, et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969–976
  91. Takai T. Multiple loss of effector cell functions in FcR gamma-deficient mice. Int Rev Immunol. 1996;13:369–381
  92. Takai T, Li M, Sylvestre D, et al.  FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76:519–529
  93. Thome M, Schneider P, Hofmann K, et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997;386:517–521
  94. Tran SE, Holmstrom TH, Ahonen M, et al.  MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem. 2001;276:16484–16490
  95. Turkson J, Bowman T, Garcia R, et al.  Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18:2545–2552
  96. Varadhachary AS, Edidin M, Hanlon AM, et al.  Phosphatidylinositol 3′-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J Immunol. 2001;166:6564–6569
  97. Verhagen AM, Vaux DL. Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis. 2002;7:163–166
  98. Vincenz C, Dixit VM. Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J Biol Chem. 1997;272:6578–6583
  99. Wajant H. The Fas signaling pathway: More than a paradigm. Science. 2002;296:1635–1636
  100. Ward SG, June CH, Olive D. PI 3-kinase: A pivotal pathway in T-cell activation?. Immunol Today. 1996;17:187–197
  101. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314–317
  102. Wei S, Gamero AM, Liu JH, et al.  Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: Identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med. 1998;187:1753–1765
  103. Wei S, Gilvary DL, Carliss BC, et al.  Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. J Immunol. 2000;165:3811–3819
  104. Winoto A, Urban JL, Lan NC, et al.  Predominant use of a V alpha gene segment in mouse T-cell receptors for cytochrome c. Nature. 1986;324:679–682
  105. Yang E, Zha J, Jockel J, et al.  Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285–291
  106. Yu CL, Meyer DJ, Campbell GS, et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81–83
  107. Zambello R, Loughran TP, Trentin L, et al.  Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes. Leukemia. 1995;9:1207–1211

☆ Supported by Veterans’ Administration Merit Review grants and NCI Grants No. CA83947 and CA90633.

PII: S0037-1963(03)00135-5

Seminars in Hematology
Volume 40, Issue 3 , Pages 213-220 , July 2003

Article Tools

* Image Usage & Resolution